The Buprenorphine Paradox: How Buprenorphine Triggers and Resolves Opioid Withdrawal.  Haghdoost M, LaBranche J, Roberts M, Li VW, Kim JJ, Wong JSH, Azar P.  Addict Biol. 2026 Mar;31(3):e70126. doi: 10.1111/adb.70126. PMID: 41802339; PMC…

Exploring the Italian Experience with Long-Acting Buprenorphine Formulations (LAIB) for the Treatment of Opioid Use Disorder: A Series of Narrative Interviews.  Ariano V, Costanzo AF, Ferrante G, Garofano R, Lamartora V, Manfré S, Nordici D, S…

Association between extended-release buprenorphine adherence and reduced healthcare costs among insured patients with opioid use disorder.  Jerry M, Venkat D, Flynn C, Tran AT, Abdel-Sattar M, Mullen W, Lane C.  Front Public Health. 2026…

More than a medication: The lived meaning and value of long-acting injectable buprenorphine.  Donaldson SR, Dillon JF, Radley A.  Drug Alcohol Depend Rep. 2026 Mar 6;19:100421. doi: 10.1016/j.dadr.2026.100421. PMID: 41859248; PMCID: PMC1…

Buprenorphine Oral Lyophilisate for Treatment of Opioid Use Disorder: Pharmacology and Clinical Efficacy.  Soyka M, Bolz S.  Pharmaceuticals (Basel). 2026 Feb 5;19(2):270. doi: 10.3390/ph19020270. PMID: 41754811; PMCID: PMC12944577. htt…

Emergency Department–Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial.  D’Onofrio G, Herring AA, Hawk KF, et al.  JAMA. Published online February 11, 2026. doi:10.1001/jama.2025.27019 Abstract https://jamane…